Protein A chromatography resin (mAb)

Life sciences tools company (Marlborough, MA; wholly-owned by Danaher Corporation since $21.4B acquisition of GE Healthcare Life Sciences in 2020) that manufactures Whatman membrane filter papers and sterile filtration products alongside its dominant chromatography resin (Capto, Sephadex, Sepharose series) and bioreactor (WAVE, XDR) platforms. Cytiva is the successor to GE Healthcare Life Sciences and Amersham Biosciences. Whatman-branded products include nitrocellulose and mixed cellulose ester membranes used in sterile filtration, diagnostics, and laboratory applications. Cytiva's role in sterile filtration is secondary to Merck KGaA and Pall — Whatman filters are more prevalent in laboratory/QC applications than primary pharmaceutical manufacturing sterilization — but Cytiva's ownership alongside Pall within Danaher creates the world's most concentrated supply position in biopharmaceutical manufacturing consumables. Danaher's combined Pall + Cytiva platform spans filtration, chromatography, bioreactors, and cell culture media — covering essentially every critical consumable step in a biologics manufacturing process.

German science and technology company (Darmstadt; family-owned since 1668; ~€22B revenue; XETRA: MRK) whose life sciences division (MilliporeSigma in North America) is the world's largest manufacturer of pharmaceutical-grade sterile filtration membranes and filter devices. Merck KGaA's filtration product lines include Durapore (PVDF, hydrophilic, 0.22 μm and 0.45 μm) — the dominant membrane for protein and buffer sterilization — and Millipore Express PLUS/SHC/SHR (PES/modified PES) for high-flow biopharmaceutical applications. Sterilizing filter devices (Millipak, Opticap XL) complete the product platform. Merck KGaA is estimated to hold ~35-40% of the global pharmaceutical sterilizing membrane market. Manufacturing is concentrated at Cork, Ireland (primary) and Jaffrey, NH and Billerica, MA (US). The Darmstadt parent that makes Durapore sterilizing filters also produces liquid crystals for LCD displays, OLED materials, photoresists for semiconductor lithography, and specialty chemicals for cosmetics — a 350-year-old German family business operating across pharmaceutical manufacturing and consumer display technology from the same corporate parent.

JSR Corporation (Tokyo; formerly JASDAQ/TSE: 4185; now private after delisting following Japan Investment Corporation nationalization in 2023) is Japan's leading life science materials company and manufacturer of Amsphere A3 Protein A affinity resin — one of the fastest-growing Protein A resin brands. JSR's Amsphere A3 uses a novel polymer bead architecture (highly cross-linked polymethacrylate) with proprietary recombinant Protein A ligand — designed for high dynamic binding capacity and long resin lifetime. In April 2023, the Japanese government's sovereign industrial fund INCJ (Innovation Network Corporation of Japan, now JIC) acquired a majority stake in JSR Corporation and took it private — an extraordinary step justified by JSR's dual strategic importance in semiconductor photoresists (JSR is the world's #2 photoresist producer, supplying TSMC and Samsung) and bioprocess materials (Amsphere A3). Japan explicitly nationalized JSR to prevent acquisition by non-Japanese parties and to secure domestic control of critical semiconductor and bioprocess supply chains — a template for strategic industry policy that no other major economy had applied to a life science materials company.

Purolite Corporation (Philadelphia PA; acquired by Ecolab Inc. NYSE: ECL for $3.7B in 2021; now Ecolab Life Sciences division) manufactures Praesto Protein A affinity resins — synthetic polymer bead-based Protein A resins designed for cost-competitive mAb purification. Purolite's Praesto AP (agarose-based) and Praesto Jetted A50 (synthetic polymer) resins offer manufacturers an alternative to Cytiva and Merck KGaA products. Purolite has manufacturing in Wales (Pontyclun UK) and Bucks County Pennsylvania. Ecolab's acquisition of Purolite for $3.7B signaled that industrial water treatment companies (Ecolab's core business) view bioprocess consumables as an adjacency to their hygiene and process chemistry businesses. Ecolab/Purolite competes with Cytiva and Merck KGaA in Protein A resins while Ecolab's water treatment division simultaneously serves the same biopharmaceutical manufacturing facilities for their utility water systems — a vertically adjacent position across multiple biomanufacturing consumable categories.

Repligen Corporation (Waltham MA; Nasdaq: RGEN; ~$700M revenue FY2024) is a bioprocessing technology company that manufactures OPUS pre-packed chromatography columns — stainless-steel-free, single-use chromatography column systems containing Protein A resin (primarily Cytiva MabSelect but also Repligen's own XCell ATF cell retention technology). Repligen's OPUS columns allow biopharmaceutical manufacturers to avoid traditional column packing and qualification steps, reducing process development time and contamination risk. Repligen also manufactures proprietary recombinant Protein A ligands (the biological binding molecule) that it supplies to third-party resin manufacturers — making Repligen a supplier to Cytiva's competitors rather than purely a downstream integrator. Repligen acquired Sweden-based ChromaTech in 2019 to expand its Protein A ligand production. Repligen's Protein A ligand business is a chokepoint within a chokepoint: the company supplies the biological molecule that multiple Protein A resin manufacturers attach to their beads.